Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M BURTON

Showing results (781-790 of 797) with videos related to

Pageof 80
Sort By:
Nature Medicine|October 27, 2018
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
The Lancet. Oncology|July 4, 2019
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma ConsortiumRodabe N Amaria, Alexander M Menzies, Elizabeth M Burton, et al.
Annals of Surgical Oncology|April 15, 2022
Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Annals of Surgical Oncology|January 28, 2022
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Nature Communications|January 13, 2021
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapyRajasekharan Somasundaram, Thomas Connelly, Robin Choi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2022
Obesity Is Associated with Altered Tumor Metabolism in Metastatic MelanomaAndrew W Hahn, Ashley V Menk, Dayana B Rivadeneira, et al.
JAMA Dermatology|July 30, 2020
Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical BenefitDouglas Grossman, Nwanneka Okwundu, Edmund K Bartlett, et al.
Nature|January 17, 2020
B cells and tertiary lymphoid structures promote immunotherapy responseBeth A Helmink, Sangeetha M Reddy, Jianjun Gao, et al.
Nature Cancer|February 13, 2024
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcomaChristina L Roland, Elise F Nassif Haddad, Emily Z Keung, et al.
Nature|June 15, 2022
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapyChristopher P Vellano, Michael G White, Miles C Andrews, et al.
Pageof 80

Showing results (781-790 of 797) with videos related to

Sort By:
Pageof 80
Nature Medicine|October 27, 2018
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
The Lancet. Oncology|July 4, 2019
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma ConsortiumRodabe N Amaria, Alexander M Menzies, Elizabeth M Burton, et al.
Annals of Surgical Oncology|April 15, 2022
Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Annals of Surgical Oncology|January 28, 2022
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Nature Communications|January 13, 2021
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapyRajasekharan Somasundaram, Thomas Connelly, Robin Choi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2022
Obesity Is Associated with Altered Tumor Metabolism in Metastatic MelanomaAndrew W Hahn, Ashley V Menk, Dayana B Rivadeneira, et al.
JAMA Dermatology|July 30, 2020
Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical BenefitDouglas Grossman, Nwanneka Okwundu, Edmund K Bartlett, et al.
Nature|January 17, 2020
B cells and tertiary lymphoid structures promote immunotherapy responseBeth A Helmink, Sangeetha M Reddy, Jianjun Gao, et al.
Nature Cancer|February 13, 2024
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcomaChristina L Roland, Elise F Nassif Haddad, Emily Z Keung, et al.
Nature|June 15, 2022
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapyChristopher P Vellano, Michael G White, Miles C Andrews, et al.
Pageof 80